These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38862612)

  • 1. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.
    Aruga Y; Ikeda C; Matsushita H; Makita S; Fukuhara S; Munakata W; Izutsu K; Matsui H
    Sci Rep; 2024 Jun; 14(1):13452. PubMed ID: 38862612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
    Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
    Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
    Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
    Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Flow Cytometry Panel for Differential Diagnosis of Mantle Cell Lymphoma from Atypical B-Chronic Lymphocytic Leukaemia.
    Mehrpouri M; Sadat Hosseini M; Jafari L; Mosleh M; Shahabi Satlsar E
    Iran Biomed J; 2023 Jan; 27(1):15-22. PubMed ID: 36624655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow.
    Bazinet A; Wang A; Li X; Jia F; Mo H; Wang W; Wang SA
    Cytometry B Clin Cytom; 2024 Jul; 106(4):264-271. PubMed ID: 36824056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
    Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
    Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
    Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
    Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
    Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
    Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples.
    Bento L; Correia R; de Sousa F; Vaz A; Pedro E; Schimidell D; Millan N; Passaro M; Barroso R; Bacal N
    Cytometry B Clin Cytom; 2020 Nov; 98(6):529-535. PubMed ID: 32251553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biclonal chronic lymphocytic leukemia: A study of two cases and review of literature.
    Ghodke KA; Patkar NV; Subramanian PG; Gujral S; Kadam PA; Tembhare PR
    Indian J Pathol Microbiol; 2017; 60(1):84-86. PubMed ID: 28195098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
    Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
    Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biclonal chronic lymphocytic leukemia.
    Hsi ED; Hoeltge G; Tubbs RR
    Am J Clin Pathol; 2000 Jun; 113(6):798-804. PubMed ID: 10874880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
    Goshaw JM; Gao Q; Wardrope J; Dogan A; Roshal M
    Cytometry B Clin Cytom; 2021 Jul; 100(4):509-518. PubMed ID: 32896973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
    Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia.
    Morabito F; De Filippi R; Laurenti L; Zirlik K; Recchia AG; Gentile M; Morelli E; Vigna E; Gigliotti V; Calemma R; Amoroso B; Neri A; Cutrona G; Ferrarini M; Molica S; Del Poeta G; Tripodo C; Pinto A
    Blood; 2011 Dec; 118(24):6353-61. PubMed ID: 21998207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
    Nguyen PC; Nguyen V; Baldwin K; Kankanige Y; Blombery P; Came N; Westerman DA
    Br J Haematol; 2023 Aug; 202(4):760-770. PubMed ID: 37052611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
    Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
    Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.